Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

41. Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial Full Text available with Trip Pro

Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics.To determine if gabapentin, a widely prescribed generic calcium channel/γ-aminobutyric acid-modulating medication, increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner.A 12-week, double-blind, placebo-controlled, randomized dose (...) -ranging trial of 150 men and women older than 18 years with current alcohol dependence, conducted from 2004 through 2010 at a single-site, outpatient clinical research facility adjoining a general medical hospital.Oral gabapentin (dosages of 0 [placebo], 900 mg, or 1800 mg/d) and concomitant manual-guided counseling.Rates of complete abstinence and no heavy drinking (coprimary) and changes in mood, sleep, and craving (secondary) over the 12-week study. RESULTS Gabapentin significantly improved

2013 EvidenceUpdates Controlled trial quality: predicted high

42. Intrathecal gabapentin to treat chronic intractable noncancer pain Full Text available with Trip Pro

Intrathecal gabapentin to treat chronic intractable noncancer pain Oral gabapentin is approved as an anticonvulsant medication and to treat postherpetic neuralgia. Its nonopioid properties and presumed spinal site of analgesic action made the study on intrathecal gabapentin attractive to establish the minimum effective dose for a later, pivotal trial.The authors examined the safety and efficacy of intrathecal gabapentin in a randomized, blinded, placebo-controlled, multicenter trial (...) in a heterogeneous cohort of candidates with chronic pain for intrathecal drug therapy.Patients (N = 170) were randomized to receive continuous intrathecal gabapentin (0 [placebo], 1, 6, or 30 mg/day) during 22 days of blinded treatment after implantation of a permanent drug delivery system. The highest dose, 30 mg/day, was selected to maintain a safety margin below the 100-mg/day dose that was explored in a phase 1 study. The authors found no statistically significant difference in the primary outcome measure

2013 EvidenceUpdates Controlled trial quality: uncertain

43. A single preoperative dose of gabapentin does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-controlled dose-finding trial (Abstract)

A single preoperative dose of gabapentin does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-controlled dose-finding trial A single preoperative dose of 600 mg gabapentin, combined with multimodal analgesia, has previously been shown to reduce postcesarean pain and improve maternal satisfaction but was associated with increased maternal sedation. We hypothesized that a lower dose of gabapentin may be effective with less sedation.We conducted a doubleblind (...) , randomized, placebo-controlled study. Women undergoing elective cesarean delivery were randomized into 3 groups to receive 300 or 600 mg oral gabapentin, or placebo, 1 hour before surgery. Temporal summation (TS) testing was performed at the time of study drug administration, and a visual analog scale (0 to 100 mm) difference ≥10 mm between the 1st and 10th stimuli was considered TS+. Spinal anesthesia and postoperative analgesia were instituted, including intrathecal fentanyl and morphine, oral

2012 EvidenceUpdates Controlled trial quality: predicted high

44. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. (Abstract)

Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Refractory chronic cough causes substantial symptoms and quality-of-life impairment. Similarities between central reflex sensitisation in refractory chronic cough and neuropathic pain suggest that neuromodulators such as gabapentin might be effective for refractory chronic cough. We established the efficacy of gabapentin in patients with refractory chronic cough.This randomised, double-blind, placebo (...) -controlled trial was undertaken at an outpatient clinic in Australia. Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks. Block randomisation was done with randomisation generator software, stratified by sex. Patients and investigators were masked to assigned treatment. The primary endpoint was change in cough-specific quality

2012 Lancet Controlled trial quality: predicted high

45. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has limited clinical value and is inferior to common analgesics

2011 ADA Center for Evidence-Based Dentistry

46. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has limited clinical value and is inferior to common analgesics

2011 ADA Center for Evidence-Based Dentistry

47. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has limited clinical value and is inferior to common analgesics

2011 ADA Center for Evidence-Based Dentistry

48. WITHDRAWN: Gabapentin for acute and chronic pain. Full Text available with Trip Pro

WITHDRAWN: Gabapentin for acute and chronic pain. February 2009: The authors are aware of unpublished trial data for Gabapentin which could affect the results of this review. This information together with that from trials published since 2005, will be considered when this review is updated in 2009.Anticonvulsant drugs have been used in the management of pain since the 1960s. The clinical impression is that they are useful for chronic neuropathic pain, especially when the pain is lancinating (...) or burning.To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice.Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966 to Nov 2004), EMBASE (1994 to Nov 2004), SIGLE (1980 to Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4, 2004). Additional studies were identified from the reference list of the retrieved papers, and by contacting investigators

2011 Cochrane

49. Horizant (gabapentin enacarbil) Extended-Release Tablets

Horizant (gabapentin enacarbil) Extended-Release Tablets Drug Approval Package: Horizant (gabapentin enacarbil) NDA #022399 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Horizant (gabapentin enacarbil) Extended-Release Tablets Company: GlaxoSmithKline Application No.: 022399 Approval Date: 4/06/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

50. Cochrane systematic review: Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term

Cochrane systematic review: Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings (...) via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clonidine, SSRIs, SNRIs and gabapentin

2011 Evidence-Based Nursing

51. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

2010 NHS Economic Evaluation Database.

52. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

53. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New users of the anticonvulsants gabapentin, lamotrigine

2010 Evidence-Based Mental Health

54. Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use

Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions There is a paucity of primary studies comparing the potential for misuse of gabapentin capsules and tablets. There is evidence from case reports that gabapentin capsules may be subject to misuse in certain populations, particularly those

2010 Health Technology Assessment (HTA) Database.

55. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials

Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

56. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials

Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct (...) and indirect meta-analyses of randomized controlled trials Chou R, Carson S, Chan B K CRD summary This review concluded that there was no difference in pain relief between gabapentin and tricyclic antidepressants in patients with diabetic neuropathy or post-herpetic neuralgia, although direct evidence was limited. The review was well conducted and these findings are likely to be reliable. Authors' objectives To compare gabapentin with tricyclic antidepressants for the treatment of diabetic neuropathy

2009 DARE.

57. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. (Abstract)

Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Drugs for neuropathic pain have incomplete efficacy and dose-limiting side-effects when given as monotherapy. We assessed the efficacy and tolerability of combined nortriptyline and gabapentin compared with each drug given alone.In this double-blind, double-dummy, crossover trial, patients with diabetic polyneuropathy or postherpetic neuralgia, and who had a daily (...) pain score of at least 4 (scale 0-10), were enrolled and treated at one study site in Canada between Nov 5, 2004, and Dec 13, 2007. 56 patients were randomised in a 1:1:1 ratio with a balanced Latin square design to receive one of three sequences of daily oral gabapentin, nortriptyline, and their combination. In sequence, a different drug was given to each randomised group in three treatment periods. During each 6-week treatment period, drug doses were titrated towards maximum tolerated dose

2009 Lancet Controlled trial quality: predicted high

58. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis

Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

59. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

60. Gabapentin for pain: New evidence from hidden data

Gabapentin for pain: New evidence from hidden data [75] Gabapentin for pain: New evidence from hidden data | Therapeutics Initiative Independent Healthcare Evidence > > [75] Gabapentin for pain: New evidence from hidden data Background Gabapentin (Neurontin) was licensed in Canada in 1993 for adjunctive treatment of epilepsy. In 1998 two double blind randomized controlled trials (DBRCT) suggested mild analgesic effects of gabapentin in painful diabetic peripheral neuropathy (PDPN) and post (...) -herpetic neuralgia (PHN) . Subsequently, unapproved use of gabapentin exploded for pain, migraine, and even as a “mood stabilizer”. (Jan-Feb 2000) reviewed gabapentin for pain. It noted that gabapentin is eliminated by kidney filtration (half-life 6 hours with normal renal function) and that it reduced pain by a mean of 1-2 points on a pain score of 0-10, over 2 weeks, NNT=4 for “moderate or marked” benefit. The Letter concluded: “Gabapentin benefits at best a minority of patients with painful diabetic

2009 Therapeutics Letter